Current Developments and Future Prospects for Plant-Made Biopharmaceuticals Against Rabies
Review
-
- Overview
-
- Research
-
- Identity
-
- Additional Document Info
-
- View All
-
Overview
abstract
-
Rabies is a prevalent health problem in developing countries. Although vaccines and immunoglobulin treatments are available, their cost and multiple-dose treatments restrict availability. During the last two decades, plants have served as a low-cost platform for biopharmaceuticals production and have been applied to fight against rabies during the last two decades. Herein, I provide a description of the state of the art in the development of plant-made pharmaceuticals against rabies and identify key prospects for the field in terms of novel strategies, immunogen design, and therapeutic antibodies production. © 2015, Springer Science%2bBusiness Media New York.
publication date
published in
Research
keywords
-
Clinical trial; Edible crop; G protein; Neutralizing antibodies; Oral vaccine; Rabies virus; Subunit vaccine Antibodies; Developing countries; Plants (botany); Viruses; Biopharmaceuticals; Biopharmaceuticals production; Clinical trial; G protein; Neutralizing antibodies; Plant-made pharmaceuticals; Subunit vaccine; Therapeutic antibodies; Vaccines; epitope; guanine nucleotide binding protein; rabies vaccine; antivirus agent; rabies vaccine; recombinant protein; human; maize; Nicotiana benthamiana; Nicotiana tabacum; nonhuman; plant root; plant seed; plant virus; protein expression; rabies; Rabies virus; Review; tobacco; tomato; economics; genetics; immunology; metabolism; rabies; transgenic plant; Antiviral Agents; Humans; Plants, Genetically Modified; Rabies; Rabies Vaccines; Recombinant Proteins
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info
start page
end page
volume
issue